Axa
VRNA

Axa’s Verona Pharma VRNA Stock Holding History

Axa’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-126,595
Closed -$12M – 995
2025
Q2 		$12M Sell
126,595
-48,800
-28% -$3.61M 0.03% 375
2025
Q1 		$11.1M Sell
175,395
-28,488
-14% -$1.7M 0.04% 363
2024
Q4 		$9.47M Sell
203,883
-74,142
-27% -$2.78M 0.03% 387
2024
Q3 		$8M Buy
+278,025
New +$6.84M 0.02% 441
2024
Q2 		– Sell
-277,784
Closed -$4.47M – 1137
2024
Q1 		$4.47M Buy
277,784
+79
+0% +$1.37K 0.01% 581
2023
Q4 		$5.52M Sell
277,705
-6,720
-2% -$99.2K 0.02% 532
2023
Q3 		$4.64M Buy
284,425
+29,666
+12% +$571K 0.02% 547
2023
Q2 		$5.39M Buy
+254,759
New +$5.43M 0.02% 538

Other funds holding VRNA

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Axa's VRNA Position: Q3 2025 in Review

Axa sold out of Verona Pharma (VRNA) in Q3 2025, closing a stake of 126,595 shares — an estimated $12M sold.

Axa first reported a position in VRNA in Q2 2023 and held it in 8 quarters. The position peaked at $12M in Q2 2025. 243 funds tracked by Wall St. Rank hold VRNA as of Q3 2025.

  • Axa reported no remaining Verona Pharma position as of Q3 2025 after selling out during the quarter.
  • Axa sold 126,595 Verona Pharma shares in Q3 2025, an estimated $12M.
  • Axa first reported a position in Verona Pharma in Q2 2023 and held it in 8 quarters.
  • Axa's Verona Pharma position peaked at $12M in Q2 2025.
  • 243 funds tracked by Wall St. Rank held Verona Pharma as of Q3 2025.

Based on Axa's 13F filing for Q3 2025, filed 14 Nov 2025.